|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
81,510,000 |
Market
Cap: |
2.05(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$17.69 - $45.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
61,250 |
176,420 |
1,153,728 |
1,608,235 |
Total Sell Value |
$1,499,251 |
$5,276,873 |
$34,770,451 |
$52,163,962 |
Total People Sold |
2 |
5 |
6 |
6 |
Total Sell Transactions |
3 |
10 |
17 |
39 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ciaramella Giuseppe |
President & CSO |
|
2023-01-03 |
4 |
OE |
$0.67 |
$51,356 |
D/D |
53,729 |
149,691 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2022-12-30 |
4 |
OE |
$0.67 |
$3,015 |
D/D |
4,500 |
95,962 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2022-12-12 |
4 |
AS |
$42.30 |
$2,178,229 |
D/D |
(51,015) |
91,462 |
|
-31% |
|
Ciaramella Giuseppe |
President & CSO |
|
2022-12-12 |
4 |
OE |
$0.67 |
$48,713 |
D/D |
26,863 |
142,477 |
|
- |
|
Evans John M. |
CEO |
|
2022-10-31 |
4 |
AS |
$44.93 |
$927,203 |
I/I |
(20,000) |
103,000 |
|
-23% |
|
Evans John M. |
CEO |
|
2022-10-31 |
4 |
AS |
$44.92 |
$1,389,225 |
D/D |
(30,000) |
1,058,520 |
|
-23% |
|
Fmr Corp |
See Remark 1 |
|
2022-09-06 |
4 |
S |
$54.25 |
$29,892 |
I/I |
(551) |
0 |
|
16% |
|
Fmr Corp |
See Remark 1 |
|
2022-09-06 |
4 |
A |
$0.00 |
$0 |
I/I |
551 |
551 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-09-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(25,620) |
0 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-08-05 |
4 |
S |
$60.50 |
$1,229,807 |
I/I |
(20,326) |
0 |
|
33% |
|
Fmr Corp |
See Remark 1 |
|
2022-08-04 |
4 |
A |
$0.00 |
$0 |
I/I |
888,573 |
2,803,027 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-08-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,342,933) |
25,620 |
|
- |
|
Evans John M. |
CEO |
|
2022-07-28 |
4 |
AS |
$64.88 |
$1,315,559 |
I/I |
(20,000) |
123,000 |
|
-32% |
|
Evans John M. |
CEO |
|
2022-07-28 |
4 |
AS |
$64.87 |
$1,972,523 |
D/D |
(30,000) |
1,088,520 |
|
-32% |
|
Evans John M. |
CEO |
|
2022-04-28 |
4 |
AS |
$36.98 |
$759,597 |
I/I |
(20,000) |
143,000 |
|
- |
|
Evans John M. |
CEO |
|
2022-04-28 |
4 |
AS |
$36.59 |
$1,139,302 |
D/D |
(30,000) |
1,118,520 |
|
- |
|
Evans John M. |
CEO |
|
2022-04-28 |
4 |
OE |
$1.03 |
$137,036 |
D/D |
59,450 |
1,148,520 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-04-13 |
4 |
S |
$50.01 |
$981,205 |
I/I |
(19,466) |
0 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-04-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,084,861 |
2,490,515 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-04-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,616,168) |
12,818 |
|
- |
|
Burrell Terry-Ann |
CFO |
|
2022-03-31 |
4 |
S |
$59.11 |
$105,630 |
D/D |
(1,787) |
38,278 |
|
- |
|
Burrell Terry-Ann |
CFO |
|
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
40,065 |
|
- |
|
Evans John M. |
CEO |
|
2022-03-31 |
4 |
S |
$59.11 |
$370,088 |
D/D |
(6,261) |
1,089,070 |
|
- |
|
Evans John M. |
CEO |
|
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
56,250 |
1,095,331 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2022-03-31 |
4 |
S |
$59.11 |
$109,885 |
D/D |
(1,859) |
115,614 |
|
- |
|
169 Records found
|
|
Page 3 of 7 |
|
|